Outcomes of Risankizumab in Patients with Crohn's Disease and Prior Ustekinumab Exposure in a Multicenter Academic Institution - PubMed
3 hours ago
- #Risankizumab
- #Ustekinumab
- #Crohn's Disease
- Risankizumab (RZB) showed symptomatic improvement in 63.2% of Crohn's disease patients with prior ustekinumab (UST) exposure.
- 83.8% of patients avoided surgery, and 48% on steroids achieved steroid-free remission with RZB treatment.
- Secondary nonresponse to UST was linked to RZB improvement, while more prior medications reduced response likelihood.